February 28, 2023 at 1:34 pm

Incannex Healthcare Takes Aim At Rheumatoid Arthritis

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), an Australian pharmaceutical company, has commenced a Phase 2 clinical trial investigating IHL-675A as a treatment for rheumatoid arthritis. The blinded, placebo-controlled study will determine the safety and effect on pain and function of IHL-675A, aproprietary fixed-dose combination drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ). Highlights Incannex’s trial… [Read More]
February 28, 2023 at 11:27 am

An Inside Look at Retail Earnings: A Bullseye for Q4 with a Cautious Outlook, Target (TGT)

Tuesday kicked off another round of big retail earnings with Target Corporation announcing their results before today’s open. General merchandise retailer, Target (TGT) beat earnings and revenue consensus reporting Q4 EPS of $1.89 vs Factset $1.40 while Q4 revenues came in at $31.4B vs Factset $30.75B. Q1 guidance indicated same-store sales from low single digit… [Read More]
February 28, 2023 at 9:55 am

Cingulate Strides Towards Delivery of All-Day ADHD Therapeutic

Biopharmaceutical company, Cingulate (Nasdaq: CING) has announced positive topline results in its fed/fast study of CTx-1301, demonstrating the drug can be taken with or without food. CTx-1301 is poised to deliver the first once-daily treatment for attention-deficit hyperactivity disorder (ADHD), a neurodevelopmental condition affecting approximately 6.4 million children and 11 million adults in the United… [Read More]
February 27, 2023 at 7:54 pm

Tesla (TSLA) Jumps 5% Ahead of Tesla Investor Day

Tesla (TSLA) jumped 5% for the day as investors are eyeing the EV company ahead of Tesla’s Investor Day. The event will take place this Wednesday at its Gigafactory in Austin, and while timing for the event has not been announced, it will be live-streamed. Some institutional and retail investors will also attend in person…. [Read More]
February 27, 2023 at 12:54 pm

Prism MarketView Index Mover: Its Electric! Fisker (FSR) Contributes Gains in the IP Emerging EV Index

An interesting reaction from the markets today on EV company Fisker Inc. (FSR) recent earnings announcement. While the company announced a greater than expected loss and missed revenues, the stock price rose in pre-market and into the open surging 30% in Monday trade. So, what’s creating the positive buzz? The company incited optimism amongst investors… [Read More]
February 24, 2023 at 9:38 pm

Timber Pharmaceuticals Secures European Orphan Drug Designation

Timber Pharmaceuticals (Nasdaq: TMBR) has received Orphan Drug Designation for TMB-001 for the treatment of X-linked recessive ichthyosis (XLRI) from the European Commission (EC). This is the company’s second orphan drug designation granted by the EC for TMB-001, which has also received the designation for the treatment of autosomal recessive congenital ichthyosis (ARCI). Highlights Medicines… [Read More]
February 24, 2023 at 9:25 pm

Verde Bio Acquires Revenue Producing Natural Gas Interests in Louisiana

 Mineral acquisitions company, Verde Bio Holdings (OTCQB: VBHI) has entered into an agreement to acquire revenue producing mineral and royalty interests in the prolific Haynesville Shale of Northern Louisiana. The company will acquire the assets, which includes natural gas interests, from a private seller for a purchase price of $425,000 in cash. Highlights The interest… [Read More]
February 24, 2023 at 2:01 pm

Chemomab Receives FDA Clearance for Phase 2 Trial

Clinical-stage biotechnology company, Chemomab (Nasdaq: CMMB) has received clearance from the FDA for its Investigational New Drug (IND) Application to evaluate CM-101 in a Phase 2 trial in adults with systemic sclerosis (SSc). CM-101 is a first-in-class monoclonal antibody designed to interfere with key biological pathways associated with SSc and other serious fibro-inflammatory diseases. In… [Read More]
February 23, 2023 at 5:38 pm

At a Glance: Featured Market Highs and Lows

Today about 65 companies (only including companies with mkt cap >$1.5B, due to volume) reached their 52-week highs while about 30 hit their 52-week lows. Industrials led with the most highs while the health technology sector saw the most lows. Let’s take a further look at a high and low of today’s market. Provider of… [Read More]
February 22, 2023 at 5:04 pm

Positive Topline Data for Inozyme Pharma

  Clinical-stage rare disease biopharmaceutical company, Inozyme Pharma (Nasdaq: INZY) has reported positive topline data from its Phase ½ clinical trial evaluating INZ-701 as a potential treatment for ENPP1 Deficiency and ABCC6 Deficiency. ENPP1 Deficiency is a progressive condition with no approved therapies. Approximately 50% of infants with ENPP1 Deficiency die within six months of… [Read More]